ZHONGHENG GROUP(SH:600252)2025-01-24 10:25Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -430 million and -220 million CNY, indicating a significant loss compared to the previous year's profit of 84.31 million CNY[3]. - The expected net profit after deducting non-recurring gains and losses for 2024 is projected to be between -400 million and -200 million CNY, compared to 22.73 million CNY in the previous year[3]. - The total profit for the previous year was 82.68 million CNY, with earnings per share of 0.0246 CNY[4]. Reasons for Expected Loss - The main reasons for the expected loss include a decline in sales volume and unit price of main products, leading to reduced revenue and gross profit[6]. - The company anticipates recognizing goodwill impairment losses not exceeding 221 million CNY due to underperformance of its subsidiary's drug sales[6]. - Non-operating gains and losses are expected to impact the financials, with around 100 million CNY related to entrusted wealth management and significant changes in the performance of some external investment projects[6]. Forecast Accuracy and Audit Status - The company has not identified any major uncertainties affecting the accuracy of this earnings forecast[7]. - The forecast data is preliminary and has not been audited by registered accountants, with final figures to be disclosed in the audited annual report[8].